These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 21535031)

  • 21. Predictors of mortality in patients with Chagas' cardiomyopathy and ventricular tachycardia not treated with implantable cardioverter-defibrillators.
    Sarabanda AV; Marin-Neto JA
    Pacing Clin Electrophysiol; 2011 Jan; 34(1):54-62. PubMed ID: 20946310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of implantable cardioverter-defibrillators in patients with Chagas disease.
    Barbosa MP; da Costa Rocha MO; de Oliveira AB; Lombardi F; Ribeiro AL
    Europace; 2013 Jul; 15(7):957-62. PubMed ID: 23376978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors affecting the all-cause death and sudden cardiac death rates of post myocardial infarction patients with low left ventricular ejection fraction.
    Dai SM; Zhang S; Chen KP; Hua W; Wang FZ; Chen X
    Chin Med J (Engl); 2009 Apr; 122(7):802-6. PubMed ID: 19493393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistent atrial fibrillation is associated with appropriate shocks and heart failure in patients with left ventricular dysfunction treated with an implantable cardioverter defibrillator.
    Rienstra M; Smit MD; Nieuwland W; Tan ES; Wiesfeld AC; Anthonio RL; Van den Berg MP; Van Veldhuisen DJ; Van Gelder IC
    Am Heart J; 2007 Jan; 153(1):120-6. PubMed ID: 17174649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy.
    Huang DT; Sesselberg HW; McNitt S; Noyes K; Andrews ML; Hall WJ; Dick A; Daubert JP; Zareba W; Moss AJ;
    J Cardiovasc Electrophysiol; 2007 Aug; 18(8):833-8. PubMed ID: 17537209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implantable cardioverter-defibrillator therapy for primary prevention of sudden cardiac death in patients with severe Chagas cardiomyopathy.
    Cardinalli-Neto A; Nakazone MA; Grassi LV; Tavares BG; Bestetti RB
    Int J Cardiol; 2011 Jul; 150(1):94-5. PubMed ID: 21497920
    [No Abstract]   [Full Text] [Related]  

  • 27. Competing risk analysis of cause-specific mortality in patients with an implantable cardioverter-defibrillator: The EVADEF cohort study.
    Marijon E; Trinquart L; Otmani A; Waintraub X; Kacet S; Clémenty J; Chatellier G; Le Heuzey JY;
    Am Heart J; 2009 Feb; 157(2):391-397.e1. PubMed ID: 19185651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical predictors and prognostic significance of electrical storm in patients with implantable cardioverter defibrillators.
    Brigadeau F; Kouakam C; Klug D; Marquié C; Duhamel A; Mizon-Gérard F; Lacroix D; Kacet S
    Eur Heart J; 2006 Mar; 27(6):700-7. PubMed ID: 16421175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of implantable cardioverter-defibrillators in patients with ischemic heart disease and left ventricular dysfunction.
    Chan PS; Chow T; Kereiakes D; Schloss EJ; Waller T; Eagle K; Hayward RA; Vijan S
    Arch Intern Med; 2006 Nov; 166(20):2228-33. PubMed ID: 17101941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention.
    Bhonsale A; James CA; Tichnell C; Murray B; Gagarin D; Philips B; Dalal D; Tedford R; Russell SD; Abraham T; Tandri H; Judge DP; Calkins H
    J Am Coll Cardiol; 2011 Sep; 58(14):1485-96. PubMed ID: 21939834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
    Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
    Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow-up of patients with chronic chagas disease and implantable cardioverter-defibrillator.
    Pereira FT; Rocha EA; Monteiro Mde P; Neto AC; Daher Ede F; Sobrinho CR; Pires Neto Rda J
    Pacing Clin Electrophysiol; 2014 Jun; 37(6):751-6. PubMed ID: 24467488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylactic implantable cardioverter defibrillator therapy in dilated cardiomyopathy: impact of left ventricular function.
    Schaer BA; Ammann P; Sticherling C; Zellweger MJ; Cron TA; Osswald S
    Int J Cardiol; 2006 Mar; 108(1):26-30. PubMed ID: 16516695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Posttraumatic stress symptoms and predicted mortality in patients with implantable cardioverter-defibrillators: results from the prospective living with an implanted cardioverter-defibrillator study.
    Ladwig KH; Baumert J; Marten-Mittag B; Kolb C; Zrenner B; Schmitt C
    Arch Gen Psychiatry; 2008 Nov; 65(11):1324-30. PubMed ID: 18981344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias.
    Healey JS; Hallstrom AP; Kuck KH; Nair G; Schron EP; Roberts RS; Morillo CA; Connolly SJ
    Eur Heart J; 2007 Jul; 28(14):1746-9. PubMed ID: 17283003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study.
    Whang W; Mittleman MA; Rich DQ; Wang PJ; Ruskin JN; Tofler GH; Muller JE; Albert CM;
    Circulation; 2004 Mar; 109(11):1386-91. PubMed ID: 14993132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mortality rates and clinical predictors of reduced survival after cardioverter defibrillator implantation.
    Thibodeau JB; Pillarisetti J; Khumri TM; Jones PG; Main ML
    Am J Cardiol; 2008 Mar; 101(6):861-4. PubMed ID: 18328854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chagas disease is associated with a worse prognosis at 1-year follow-up after implantable cardioverter-defibrillator for secondary prevention in heart failure patients.
    Vieira de Melo RM; de Azevedo DFC; Lira YM; Cardoso de Oliveira NF; Passos LCS
    J Cardiovasc Electrophysiol; 2019 Nov; 30(11):2448-2452. PubMed ID: 31502385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sudden cardiac death in Chagas' heart disease in the contemporary era.
    Bestetti RB; Cardinalli-Neto A
    Int J Cardiol; 2008 Dec; 131(1):9-17. PubMed ID: 18692919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of anemia in patients with chronic systolic heart failure secondary to Chagas' cardiomyopathy.
    Miguel CE; Bortoluzzi TB; Otaviano AP; Cardinalli-Neto A; Rocha BF; Ferrari SJ; Bestetti RB
    Acta Trop; 2011 Dec; 120(3):219-23. PubMed ID: 21906579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.